轩竹生物：17载新药研发 叩开港股大门

Core Viewpoint - Xuanzhu Biotechnology successfully listed on the Hong Kong Stock Exchange, becoming the first new listed company in Shijiazhuang this year, marking a significant milestone for the company and the local biotech industry [1] Company Overview - Xuanzhu Biotechnology focuses on the research and development of innovative drugs for major diseases such as digestive system diseases, tumors, and non-alcoholic fatty liver disease, having started its R&D efforts in 2008 [2] - The company is recognized as a unicorn and was introduced to Shijiazhuang from Hainan in 2020, establishing itself in the Shijiazhuang International Biopharmaceutical Park [2] Financial Aspects - The company has faced challenges in securing funding for its high-investment, high-risk drug development projects, often needing to approach dozens to hundreds of investment institutions for financing [2][3] - In September 2023, the company received a timely 10 million yuan biopharmaceutical R&D reward from Shijiazhuang, providing a significant boost to its innovation efforts [2] Recent Developments - Xuanzhu Biotechnology has successfully launched three innovative drugs: Annelazole Sodium, Pyrocyclic, and Diroac, demonstrating steady progress in its R&D journey [3] - The company submitted its listing application to the Hong Kong Stock Exchange in November 2024, aiming to leverage direct financing for core product development, production, and commercialization [3] Government Support - Various levels of government provided strong support during the listing process, including financial loan assistance and expedited administrative approvals, which significantly reduced the time required for compliance documentation [3] Fundraising and Future Plans - The company issued 67.33 million shares at an offering price of 11.60 HKD per share, raising a total of 780 million HKD, which will primarily be used for R&D and commercialization in its core therapeutic areas [4]